These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21539403)

  • 21. Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study.
    Strajhar P; Vizeli P; Patt M; Dolder PC; Kratschmar DV; Liechti ME; Odermatt A
    J Steroid Biochem Mol Biol; 2019 Feb; 186():212-225. PubMed ID: 30381248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and armodafinil in healthy adult males undergoing acute sleep loss.
    Gasior M; Freeman J; Zammit G; Donnelly P; Gao J; Ferreira-Cornwell MC; Roth T
    J Clin Psychopharmacol; 2014 Dec; 34(6):690-6. PubMed ID: 25159886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
    Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
    Jasinski DR; Krishnan S
    J Psychopharmacol; 2009 Jun; 23(4):419-27. PubMed ID: 19329547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
    Adler LA; Alperin S; Leon T; Faraone SV
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic and exposure-response analyses of d-amphetamine after administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD patients.
    Tsuda Y; Matsuo Y; Matsumoto S; Wajima T
    Drug Metab Pharmacokinet; 2020 Dec; 35(6):548-554. PubMed ID: 33082099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults.
    Faison SL; Fry N; Adewole T; Odebo O; Wang Z; Maletic V; Nasser A
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):155-162. PubMed ID: 33587403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lisdexamfetamine and amphetamine pharmacokinetics in oral fluid, plasma, and urine after controlled oral administration of lisdexamfetamine.
    Comiran E; Carlos G; Barreto F; Pechanksy F; Fröehlich PE; Limberger RP
    Biopharm Drug Dispos; 2021 Jan; 42(1):3-11. PubMed ID: 33119133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisdexamfetamine.
    Blick SK; Keating GM
    Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
    J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Wigal T; Brams M; Gasior M; Gao J; Giblin J
    Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.
    Ermer JC; Pennick M; Frick G
    Clin Drug Investig; 2016 May; 36(5):341-56. PubMed ID: 27021968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T; Dirks B; Adeyi B; Scheckner B
    BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study.
    Darwish M; Hellriegel ET; Xie F
    Clin Drug Investig; 2008; 28(12):793-801. PubMed ID: 18991473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
    Ermer J; Corcoran M; Martin P
    Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Infant with a Prolonged Sympathomimetic Toxidrome after Lisdexamfetamine Dimesylate Ingestion.
    Wood KE; Krasowski MD
    J Med Toxicol; 2016 Dec; 12(4):402-405. PubMed ID: 27277955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
    Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
    Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.